Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts

por Bota, Daniela A, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A, Kong, Xiao-Tang, Fu, Beverly D, Hsu, Frank PK, Schönthal, Axel H, Hofman, Florence M, Chen, Thomas C, Zidovetzki, Raphael, Pretto, Chrystel, Strik, Ankie, Schijns, Virgil EJC, Stathopoulos, Apostolos
Publicado 2018

Therapeutic Immunization against Glioblastoma

por Schijns, Virgil E. J. C., Pretto, Chrystel, Strik, Anna M., Gloudemans-Rijkers, Rianne, Devillers, Laurent, Pierre, Denis, Chung, Jinah, Dandekar, Manisha, Carrillo, Jose A., Kong, Xiao-Tang, Fu, Beverly D., Hsu, Frank P. K., Hofman, Florence M., Chen, Thomas C., Zidovetzki, Raphael, Bota, Daniela A., Stathopoulos, Apostolos
Publicado 2018